Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early software-assisted response predicts survival in a prospective cohort of 258 newly diagnosed cGvHD patients.

Bone marrow transplantation·2026
Same author

Dynamics of IDH1/2 mutated clones in acute myeloid leukemia challenge their use as universal MRD markers.

Blood cancer journal·2026
Same author

Association of hypomethylating agents + venetoclax in the real-life treatment of Myeloproliferative Neoplasms in blastic phase.

Leukemia research·2026
Same author

APL-like subset within <i>NPM1</i>-mutated AML: A distinct immunophenotype correlating with early vascular complications.

HemaSphere·2026
Same author

Phase 1/2 trials of donor regulatory T cells for the treatment of steroid-refractory chronic graft-versus-host disease.

Blood advances·2026
Same author

Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort.

Journal of hematology & oncology·2025

Related Experiment Video

Updated: May 4, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

951

Immunotherapy in acute myeloid leukemia.

Mario Arpinati1, Antonio Curti

  • 1Department of Hematology & Oncological Sciences 'Seragnoli', University of Bologna, Italy.

Immunotherapy
|December 18, 2013
PubMed
Summary

Current acute myeloid leukemia (AML) treatments show poor survival rates. Immunotherapy, particularly harnessing the graft-versus-leukemia (GVL) effect from allogeneic stem cell transplants, offers a promising avenue for improved cure rates by leveraging immune responses against leukemia.

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

13.6K
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

20.8K

Related Experiment Videos

Last Updated: May 4, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

951
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

13.6K
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

20.8K

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • Acute myeloid leukemia (AML) treatment outcomes remain suboptimal, with survival rates below 40% at 5 years.
  • AML cells employ mechanisms like indoleamine 2,3 dioxygenase expression to evade immune detection.
  • Existing immunotherapies show potential but face challenges in overcoming leukemia escape.

Purpose of the Study:

  • To explore immunotherapeutic strategies for overcoming immune evasion in AML.
  • To investigate methods for enhancing the graft-versus-leukemia (GVL) effect.
  • To develop strategies for increasing leukemia-reactive T cells with minimized graft-versus-host disease.

Main Methods:

  • Review of current AML treatment limitations and immune evasion tactics.
  • Analysis of allogeneic hemopoietic stem cell transplantation as a model for immunotherapy and GVL.
  • Examination of T cell-mediated GVL and its association with graft-versus-host disease.

Main Results:

  • Allogeneic stem cell transplantation demonstrates the most effective AML treatment via the GVL effect.
  • GVL is mediated by donor T cells recognizing leukemia-associated or histocompatibility antigens.
  • Graft-versus-host disease remains a significant cause of mortality post-transplant.

Conclusions:

  • Innovative strategies are needed to generate leukemia-reactive T cells to improve GVL responses.
  • Minimizing graft-versus-host disease while maximizing GVL is crucial for effective immunotherapy.
  • Further research into T cell-based immunotherapies holds promise for enhanced AML cure rates.